Drug Evaluation during the Covid-19 Pandemic

N Engl J Med. 2020 Jun 11;382(24):2282-2284. doi: 10.1056/NEJMp2009457. Epub 2020 Apr 14.

Authors

Benjamin N Rome¹, Jerry Avorn¹

Affiliation

¹ From the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston.

PMID: 32289216
DOI: 10.1056/NEJMp2009457

No abstract available

MeSH terms

Betacoronavirus
COVID-19
COVID-19 Drug Treatment
Chloroquine / supply & distribution
Chloroquine / therapeutic use
Clinical Trials as Topic
Coronavirus Infections / drug therapy*
Drug Approval*
Drug Evaluation / standards*
Drugs, Investigational / therapeutic use
Humans
Hydroxychloroquine / supply & distribution
Hydroxychloroquine / therapeutic use
Off-Label Use
Pandemics
Pneumonia, Viral / drug therapy*
SARS-CoV-2
United States
United States Food and Drug Administration

Substances

Drugs, Investigational
Hydroxychloroquine
Chloroquine